@article{3120454,
    title = "Interpreting the results of the VERTIS-CV trial: Is this the end of the “class effect” perspective? [解读VERTIS-CV试验的结果:这是“类效应”视角的终结吗?]",
    author = "Koufakis, T. and Papanas, N. and Dimitriadis, G. and Zebekakis, P. and Kotsa, K.",
    journal = "WORLD JOURNAL OF DIABETES",
    year = "2020",
    volume = "12",
    number = "12",
    pages = "942-945",
    publisher = "John Wiley and Sons Inc",
    doi = "10.1111/1753-0407.13105",
    keywords = "ertugliflozin;  hemoglobin A1c;  ertugliflozin;  fused heterocyclic rings;  glycosylated hemoglobin, all cause mortality;  body mass;  drug efficacy;  drug safety;  drug screening;  estimated glomerular filtration rate;  hemoglobin blood level;  hospital admission;  hospitalization;  human;  incidence;  non insulin dependent diabetes mellitus;  Note;  priority journal;  randomized controlled trial (topic);  treatment outcome;  trend study;  aged;  blood;  cardiovascular disease;  clinical trial;  controlled study;  follow up;  glucose blood level;  metabolism;  middle aged;  non insulin dependent diabetes mellitus;  phase 3 clinical trial;  procedures;  randomized controlled trial, Aged;  Blood Glucose;  Bridged Bicyclo Compounds, Heterocyclic;  Cardiovascular Diseases;  Diabetes Mellitus, Type 2;  Follow-Up Studies;  Glycated Hemoglobin A;  Humans;  Middle Aged;  Outcome Assessment, Health Care;  Sodium-Glucose Transporter 2 Inhibitors"
}